Abstract
ATP-sensitive potassium channels (KATP) are involved in a diverse array of physiologic functions including protection of tissue against ischemic insult, regulation of vascular tone, and modulation of insulin secretion. To improve our understanding of the role of KATP in these processes, we used a gene-targeting strategy to generate mice with a disruption in the muscle-specific KATP regulatory subunit, SUR2. Insertional mutagenesis of the Sur2 locus generated homozygous null (Sur2−/−) mice and heterozygote (Sur2+/−) mice that are viable and phenotypically similar to their wild-type littermates to 6 weeks of age despite, respectively, half or no SUR2 mRNA expression or channel activity in skeletal muscle or heart. Sur2−/− animals had lower fasting and fed serum glucose, exhibited improved glucose tolerance during a glucose tolerance test, and demonstrated a more rapid and severe hypoglycemia after administration of insulin. Enhanced glucose use was also observed during in vivo hyperinsulinemic euglycemic clamp studies during which Sur2−/− mice required a greater glucose infusion rate to maintain a target blood glucose level. Enhanced insulin action was intrinsic to the skeletal muscle, as in vitro insulin-stimulated glucose transport was 1.5-fold greater in Sur2−/− muscle than in wild type. Thus, membrane excitability and KATP activity, to our knowledge, seem to be new components of the insulin-stimulated glucose uptake mechanism, suggesting possible future therapeutic approaches for individuals suffering from diabetes mellitus.
Distinct isoforms of the ATP-sensitive potassium channel (KATP) are expressed in many tissues including pancreatic β cells, striated and smooth muscle cells, and neurons (1, 2). This inwardly rectifying potassium-selective channel is composed of a hetero-octomer of four regulatory SUR subunits and four potassium pore proteins, Kir6.1 or Kir6.2 (3). In β cells SUR1 and Kir6.2 form the KATP channel that is closed in response to the sulfonylurea hypoglycemic drugs (4), stimulating insulin secretion. In the periphery, SUR2 is the primary regulatory subunit expressed in muscle cells, and it pairs with Kir6.1 in vascular smooth muscle and Kir6.2 in skeletal and cardiac muscle (5). SUR2 undergoes multiple tissue-specific splicing that regulates both its sensitivity to inhibition by nucleotides and its response to pharmacological agents (5, 6). Physiologically, the cardiac KATP channel apparently functions in repolarizing the membrane in the latter part of the action potential (7). Opening of the KATP channel during short periods of ischemia protects the heart from subsequent ischemic insults by a process known as ischemic preconditioning (8, 9). The vascular KATP channel plays a role in regulation of vascular tone, and treatment with agents such as diazoxide and pinacidil, which open the KATP channel, results in vasodilatation (6). In skeletal muscle, the function of the KATP channel is less well defined, but it may also be responsible for protection against ischemic damage (10).
Disruption of Kir6.2 in mice results in both β cell failure and an increased responsiveness to injected i.p. insulin with a more pronounced hypoglycemic response than that of wild-type mice (11). The enhanced insulin action in this model could be caused by a direct effect of the disruption of the KATP channel in peripheral tissues, or to compensation for the progressive β cell failure and subsequent persistent hyperglycemia. In this report, we find that a disruptive mutation of Sur2 in mice does not result in altered β cell morphology or circulating insulin levels but does lead to an enhanced ability of insulin to increase peripheral glucose disposal by directly increasing the intrinsic insulin responsiveness of skeletal muscle. This result suggests a direct role for the KATP channel in insulin signaling.
Materials and Methods
Sur2 Targeting Vector Construction.
PCR-generated genomic fragments were inserted into a positive/negative selection pPNT (7.2 kb) plasmid for targeting vector construction (12): The 5′ arm spanned exons 10–12 (forward: 5′-GAGCGTGGAGGAGACACGAATGAAGGAG-3′; reverse 5′-GCTCTAGAGGCTTCAGGTTGTTTCCACTGGCG-3′). The 3′ arm of homology spanned intron 17 to exon 21 (forward: 5′-TAAACTATCCTGCAGGCAACTAGGGGAGGGAGGGAAGGGGC-3′; reverse 5′-AAGGAAAAAAGCGGCCGCAGGATTCCTTCCTGCATCAAATGATCGCTCAG-3′). PCR products and subcloning products were sequenced to confirm identity and proper orientation.
Generation of Sur2+/− ES Cells.
Positive/negative selection of ES cells (Genome Systems, St. Louis) transfectants with neomycin resistance was performed by postelectroporation growth in G418 and gancyclovir for 10–12 days. Positive clones for homologous recombination were identified by PCR and confirmed by Southern blot analysis after NcoI digestion by using a labeled 800-bp NcoI/BamHI genomic fragment probe outside of, and 5′ to, the region of the targeting vector.
Generation of Sur2+/− Chimeric and Germ-Line Mice.
Animal experimentation was performed according to National Institutes of Health guidelines in the FMI animal facility of the University of Chicago and approved by the Institutional Animal Care and Use Committee. ES cells from two independently targeted Sur2+/− generated clones were microinjected into C57BL/6 donor blastocysts, which were then implanted into pseudopregnant CD1 foster mothers (13). Resulting male chimeric mice were bred to CD1 females, and heterozygous Sur2+/− mice were interbred or bred to CD1 animals to generate further offspring for phenotypic analysis.
Southern and Northern Blot Analysis.
Genomic DNA was isolated from mouse tail clippings via overnight proteinase K digestion as described (14), digested with NcoI, resolved on 1% agarose gels, and transferred to nylon membranes. The 800-bp 32P-labeled genomic fragment (5′N/B probe, Fig. 1) was hybridized overnight in 5× SSPE [standard saline phosphate/EDTA (0.18 M NaCl/10 mM phosphate, pH 7.4/1 mM EDTA)], 5× Denhardt's solution (0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% BSA), 0.5% SDS, and single-stranded DNA at 100 μl/ml at 65°C. Labeled fragments were quantitated by PhosphorImaging (Molecular Dynamics). Total RNA was isolated from individual tissues by TRIzol extraction (GIBCO/BRL). RNA (20 μg) was resolved in 1% formaldehyde-agarose gels. Skeletal muscle and heart samples were probed with a 32P-labeled 4,231-bp (0–4231) fragment of SUR2 cDNA or full-length human GLUT4 cDNA.
Figure 1.
Generation and evaluation of SUR2 mutant mice. (A) Schematic of the mouse Sur2 targeting strategy. Exons are shaded in gray, and functional motifs are depicted above the exons. TM, predicted transmembrane spanning domain; Neo, neomyicin resistance gene; TK, thymidine kinase sequences. Walker A and B motifs are identified as black boxes. Restriction sites are indicated: B, BamHI; N, NcoI; S, Sse838; X, XbaI. Open triangles, the NcoI sites for Southern blot analysis. The probe used for Southern analysis is shown below the targeted allele. (B) Northern blot analysis of heart and skeletal muscle for Sur2+/+, Sur2+/−, and Sur2−/− mice. (Upper) Autoradiogram of total RNA probed with a 32P-labeled Sur2 cDNA probe (bp 0–4231). (Lower) Ethidium bromide staining of the 28S ribosomal subunit. (C) Sur2 genotyping. NcoI-digested genomic DNA was hybridized with the 32P-labeled probe depicted in the schematic. +/+, wild type; +/−, heterozygote; −/−, homozygote mutant allele. The ratio of the labeled fragment signal intensities for wild-type-to-mutant alleles differentiates heterozygotes (2:1) from homozygotes (1:1). (D) Single-channel current recordings in open-cell-attached mode from ventricular myocytes of Sur2+/+ (upper tracing) and Sur2−/− (lower tracing). At −40 mV, open current activity is shown as a downward deflection.
Western Blot Analysis.
Skeletal muscle and cardiac muscle microsomes were prepared as described (15). Microsomal membrane protein was resolved on SDS/10% polyacrylamide gels and transferred to PVDF membranes (Gelman Science, Ann Arbor, MI). Immunoblotting was performed with anti-GLUT4 antibodies (Biogenesis, Bournemouth, U.K.) at 1:1,000 titer, and detected with enhanced chemiluminesence (Pierce).
Serum Chemistry.
Whole blood glucose was determined with a Hemocue glucometer (Angelholm, Sweden); serum triglycerides were determined by using a colorimetric assay (Wako Chemicals, Richmond, VA); and insulin concentrations were measured by RIA (Linco Research Immunoassay, St. Louis) with use of rat insulin standards.
Cardiac Myocyte Patch Clamping.
Viable ventricular muscle cells were enzymatically isolated from mice 4 months of age by a standard Langendorf perfusion method (16). Voltage clamp methods for KATP channels were standard as reported (5). The excised inside-out patch method was used with standard solutions with symmetrical 140 mM KCl and 1 μM ATP in the bath.
Intraperitoneal Glucose and Insulin Tolerance Tests.
Glucose tolerance tests were performed after a 4-h fast followed by an i.p. injection of glucose at 2 g/kg body mass (2 g/kg). Insulin tolerance tests were performed on postprandial mice by an i.p. injection of 0.5 unit human regular insulin per kg body mass (0.5 u/kg). Blood glucose levels were assayed from tail vein blood.
Hyperinsulinemic Euglycemic Clamp.
Clamp studies were performed as described (17). A sterile PE-10 tubing catheter was inserted into the left jugular vein under isoflurane general anesthesia, and externalized through an incision in the skin flap behind the head. On postoperative day 4, after an overnight fast, a 240-min hyperinsulinemic-euglycemic clamp was performed by continuous infusion of regular human insulin at a rate of 15 pmol⋅kg−1⋅min−1. Tail vein blood samples were collected at 10-min intervals for the immediate measurement of plasma glucose, and 20% glucose was infused at a varying rate to maintain plasma glucose at basal concentrations of 125 ± 5 mg/dl. Whole body glucose disposal was calculated as the integral of the rate of glucose infusion during the period of blood glucose clamping.
In Vitro Glucose Transport Assay.
Glucose transport activity was measured as described (18). Intact soleus muscles, dissected from 8-week-old males, were preincubated for 15 min at 35°C in 2 ml of Krebs–Henseleit bicarbonate buffer, under 5% CO2. The media were supplemented with 2 mM pyruvate, 0.1% BSA, and either regular insulin at 2,000 microunits/ml or in the absence of insulin. Muscles were transferred to fresh Krebs–Henseleit bicarbonate buffer preincubation buffer with the addition of 0.1 mM 2-[3H]deoxyglucose (0.5 μCi/mmol, Amersham Pharmacia), 0.1 mM [14C]sucrose (0.2 μCi/mmol, Amersham Pharmacia), 0.5 M 2-[3H]deoxyglucose, 50 mM sucrose, and the same insulin concentrations used for sample preincubation, then incubated at 35°C for 15 min. The extracellular space and intracellular 2-[3H]deoxyglucose concentration (micromoles per milliliter of intracellular water) were determined by scintillation counting (19).
Statistical Analysis.
Values are reported as mean ± SEM. P values were calculated by ANOVA or the Student's t test.
Results
Generation of Sur2−/− Mice.
Human SUR1 intron/exon boundaries proved to be highly accurate predictors for the mouse Sur2 genomic structure with all of the exons preserved between the two genes and with nearly identical intron/exon boundaries. Sur2 consists of a minimum of 39 coding exons, the last exon serving as an alternate carboxy-tail variant (20). Previously, we noted two variant sequences in the 5′-untranslated region, suggesting the possibility of alternate transcriptional start sites (1); thus, a “functional knockout” strategy was undertaken. Two arms of homology were generated for the targeting vector that spanned, respectively, intron 10 to exon 12 and intron 17 to exon 21. The deleted domain encompassed the ATP-binding domain of the first nucleotide-binding fold (Walker A motif) and a single predicted transmembrane-spanning domain preceding nucleotide-binding fold 1 (Fig. 1A). During F2 offspring genotyping, it became evident that the original stem cell targeting, from which the founder male developed, had an additional integration event involving a duplication of the Sur2 locus between exons 9 and 27. The duplicated segment integrated 3′ to the Sur2 locus as determined by long-range genomic PCR and fluorescence in situ hybridization (not shown). However, the native Sur2 locus was properly targeted and disrupted, because half the amount of mRNA for Sur2 was found in heart and skeletal muscle of the heterozygous mice and no mRNA was detected for Sur2 in the homozygous mutant mice (Fig. 2B). Sequencing of the 5′ and 3′ targeting boundaries confirmed the proper integration of the targeting vector. Southern blot of NcoI-digested genomic DNA from heterozygous mice showed a 6.0-kb fragment (wild-type allele) and a single predicted 4.3-kb mutant allele fragment. The ratio of wild-type to mutant hybridizing intensities is 2:1 as determined by densitometry, which indicates one wild-type allele and a mutant allele that consists of a “wild-type” fragment (the duplicated segment) and the disrupted fragment. Homozygous mutant animals, then, have 1:1 intensity of the mutant 4.3-kb fragment and the 6.0-kb duplicated wild-type segment (Fig. 1C). Unambiguous genotyping is thus possible by Southern blotting and by PCR. The absence of KATP currents in patches isolated from cardiac myocytes (Fig. 1D) and skeletal muscle (not shown) confirmed Sur2 disruption. In 55 patches from cells isolated from three different Sur2−/− mice, no KATP currents were observed. In 23 patches from four different Sur2+/−mice, KATP activity was seen in four patches (17%). In 26 patches from wild-type littermates, KATP currents were detected in 19 patches (74%).
Figure 2.
(A) Weight gain in male mice with unrestricted access to standard chow. Weights are expressed as mean values ± SEM. (B) Serum glucose, insulin, and triglyceride levels for wild-type and Sur2−/− mice between 10 and 12 weeks of age, both in the fasted and fed states. Significance of values between wild-type and Sur2−/− mice are indicated. n.s., nonsignificant. (C) Response of mice to i.p. injection of glucose (2 g/kg). Serum glucose levels at the indicated time points are expressed as mean values ± SEM (D) i.p. insulin tolerance test. Glucose levels were determined in mice injected i.p. with insulin (0.5 U/kg). Values are mean ± SEM (E) Representative hyperinsulinemic, euglycemic clamp assays from Sur2+/+ (Left) and Sur2−/− (Right) mice. Mice were infused with a constant rate of insulin and variable glucose as described in Materials and Methods. The closed circles represent the blood glucose levels, and the gray region represents the target blood glucose range. Open diamonds represent the rate of glucose infusion from a 20% glucose solution. A compilation of the rates of glucose infusion is summarized as a bar graph, with an n = 3 for Sur2+/+ mice and an n = 3 for Sur2−/− (Right) mice. *, P < 0.05.
Physiology of Sur2+/− and Sur2−/− Mice.
Homozygous and heterozygous mice showed normal growth until 6 weeks of age, when their weight gain began to lag compared with that of the wild-type animals (Fig. 2A). Increased spontaneous mortality in male Sur2−/− mice was observed at 6 weeks of age and in females at 10 weeks of age (W.A.C., J.P., J.C.M., C.F.B., and E. McNally, unpublished work). Serum chemistry, performed on fasted 6- to 8-week-old mice, showed that Sur2 disruption did not result in changes in serum electrolytes compared with wild-type littermates (data not shown). There was a small but significant decrease in serum glucose levels, although a nonsignificant difference in serum insulin levels, in Sur2−/− mice compared with wild-type controls in both the fasting and fed state (Fig. 2B). There was no change in fed or fasting serum triglyceride concentration in male Sur2−/− vs. wild-type mice (Fig. 2B).
Assessment of Glucose and Insulin Tolerance.
i.p. administration of 2 g/kg of glucose to wild-type mice resulted in a typical increase in glucose levels to a peak of 420 mg/dl. The Sur2+/− mice had identical baseline glucose levels and a relatively normal response to the glucose load. Sur2−/− mice again had decreased fasting glucose concentrations and showed a significantly improved glucose tolerance curve, with peak glucose of ≈250 mg/dl (Fig. 2C). To test insulin sensitivity further, wild-type and Sur2−/− mice were challenged with 0.5 U/kg of insulin. Wild-type mice showed a transient decrease in blood glucose, whereas the Sur2−/− mice showed a rapid and sustained reduction in serum glucose, with half the mice either succumbing to hypoglycemia or requiring glucose injections to restore glucose levels (Fig. 2D). Again, heterozygous mice, like wild-type mice, showed a typical decrease and rebound in serum glucose after insulin challenge. Whole-body glucose disposal was assessed by an euglycemic, hyperinsulinemic clamp, providing a more discriminating indicator of insulin action. The Sur2−/− mice not only required a greater glucose infusion to maintain target serum glucose levels than wild-type mice did, 51.5 mg⋅kg−1⋅min−1 vs. 33.9 mg⋅kg−1⋅min−1, respectively (P < 0.05; Fig. 2E), but merely maintaining target blood glucose levels proved difficult in Sur2−/− mice, despite a continuously increasing glucose infusion rate.
Insulin Responsiveness in Isolated Skeletal Muscle.
The uptake of 2-[14C]deoxyglucose by incubated soleus muscle in the absence of insulin (“basal glucose transport”) was not different between Sur2−/− mice and wild-type mice. However, there was a significant 59% increase in glucose uptake after incubation with 2,000 microunits/ml insulin (Fig. 3A). There was no change in the levels of GLUT4 mRNA (data not shown) or protein (Fig. 3B) in the Sur2+/− or Sur2−/− mice from their wild-type littermates.
Figure 3.
(A) In vitro 2-[14C]deoxyglucose uptake into the soleus muscle of male Sur2+/+ and Sur2−/− mice. Soleus muscles were incubated in the absence of insulin (basal transport) or high insulin (2,000 microunits/ml) before and during transport study. Bars represent mean ± SEM, n = 5, for each group. *, P < 0.04 vs. Sur2+/+ mice. (B) Representative Western blot of hindlimb skeletal muscle of Sur2+/+, Sur2 +/−, and Sur2−/− mice. The microsomal fraction was separated by SDS/PAGE and probed with anti-GLUT4 antiserum. 2-DG, 2-[3H]deoxyglucose.
Discussion
We demonstrated that eliminating muscle KATP channel currents in mice by disrupting Sur2 results in increased insulin responsiveness in skeletal muscle. Because SUR2 is not expressed in pancreatic tissue, it is not surprising that gross pancreatic function is undisturbed in this model, as evidenced by the normal fasting and fed insulin levels and unaltered islet architecture of Sur2−/− mice (islet histology not shown). Furthermore, basal glucose homeostasis is minimally affected with only small albeit significant decreases in baseline serum glucose concentration. The role of the skeletal muscle KATP channel then, and likely membrane excitability, represents an intriguing facet of the insulin-signaling pathway. Early postreceptor signaling steps in insulin action have been established and include increases in phosphorylation of insulin receptors and substrates that lead to a rapid increase in glucose uptake (21). Late steps have also been studied extensively and involve translocation of glucose transporters (GLUT4) from subcellular vesicle stores to the sarcolemma, with vesicle fusion increasing membrane permeability to glucose (22). The intermediate steps are less well understood. One well-characterized postinsulin/receptor binding event is the activation of the Na/K-ATPase cotransporter, which leads to a hyperpolarization of the membrane (23). Increased Na/K-ATPase activity has been associated with an increase in glycolytic flux by increasing the supply of ADP necessary for early steps in glucose metabolism (26).
The role of changes in membrane potential regarding insulin action is not clearly defined. Insulin treatment of skeletal muscle has long been known to hyperpolarize the skeletal muscle membrane (25–27), and insulin-induced hyperpolarization has been proposed as a transducing mechanism mediating insulin action (28, 29). Supporting this hypothesis, artificial hyperpolarization of skeletal muscle has been shown to stimulate glucose uptake (30). In addition, insulin opens KATP channels, which would also lead to increased skeletal muscle hyperpolarization (31), possibly implicating KATP as a component of insulin-induced hyperpolarization.
In contrast, past reports suggest that inhibiting KATP channels with sulfonylureas, which should lead to cell membrane depolarization, also enhances insulin-stimulated glucose uptake, whereas KATP channel openers inhibit the effect (32–37). The seemingly contradicting evidence between this mechanism and insulin-induced hyperpolarization underscores a complex series of excitation events occurring at the skeletal muscle membrane after insulin binds to its receptor. Zierler and Wu (38) reported that insulin-induced hyperpolarization was the consequence of a reduction in both potassium and sodium permeability—the greater relative diminishment in sodium permeability, such that PK > PNa, leads to hyperpolarization. It has also been proposed that KATP channels mediate the efflux of potassium after stimulation of the Na/K-ATPase (39). The KATP channel role certainly might not reflect an initial signaling event, but it may involve subsequent steps such as restoring the resting membrane potential. Thus, an initial hyperpolarization, whether through activation of the Na/K-ATPase or via other mechanisms, may be important in initiating a sequence of events leading to increased glucose transport, whereas opening the KATP channel results in termination of the signal. In the absence of insulin, then, little effect of the disruption of the KATP channel should be seen, which is consistent with the normal basal glucose uptake in our isolated muscle transport studies, and enhanced transport after insulin stimulation. Also consistent are our in vivo observations that only a small decrease in basal glucose levels are seen, but a marked and increasing rate of glucose infusion is needed to maintain a target blood glucose level for the Sur2−/− mice during a hyperinsulinemic-euglycemic clamp (Fig. 2C). These observations suggest that eliminating the muscle KATP channel results in a defect in dissipation of the insulin signal.
Although we demonstrated a defect intrinsic to the skeletal muscle, it is also possible that alterations in vascular flow caused by an absence in vascular smooth muscle KATP current affect glucose delivery to skeletal muscle. Indeed, increases in blood flow have been shown to correlate with insulin-mediated glucose uptake (40), and it has been suggested that insulin directly induces vasodilatation, perhaps through an NO-mediated event (41). Although we have detected a significant elevation of blood pressure in the Sur2−/− mice (W.A.C., J.P., J.C.M., C.F.B., and E. McNally, unpublished work), insulin-mediated vasodilatation may still occur and perhaps be enhanced because of the disruption of KATP.
In summary, the SUR2 KATP channel apparently is important for regulation of insulin signaling in skeletal muscle. These findings shed light on the observations of Kir6.2 null mice, which lack both β cell KATP and skeletal muscle KATP (11). The enhanced peripheral insulin responsiveness demonstrated in the absence of extra-pancreatic KATP can provide a direct account for the survival of Kir6.2 null mice, despite their significantly reduced circulating insulin levels and blunted β cell response. Our findings also suggest a mechanism for the small enhancement of insulin action in the periphery by sulfonylureas. Because the sulfonyureas have up to a 100-fold lower affinity for SUR2-containing potassium channels as for the SUR1-containing channels (42), it may be possible to design specific high-affinity inhibitors of this channel that could allow enhanced insulin action. In addition, studies focusing on membrane excitability and its function in insulin action may provide a key link between early postinsulin signaling events and the late events that result in GLUT4 vesicle translocation and increased glucose transport.
Acknowledgments
We thank Jon Davison for his technical contributions to the in vitro glucose transport studies and Kevin Galles for his technical work in breeding mice and isolating cardiac myocytes. We also thank Linda Degenstein for her expert technical work in stem cell/blastocyst injection and the generation of the transgenic animals. We are grateful to Drs. Graeme Bell, Lou Philipson, and Donald Steiner for critically reading drafts of this manuscript. Finally, we thank Dr. Kenneth Polonsky for his support toward initiating this project and the generation of the knockout mice. This work was supported by funding from the National Institutes of Heath Grants DK-KO8-02170 (C.F.B.) and RO1 HL-57414 (J.C.M.), and the Oscar Rennebohm Foundation (J.C.M.).
Abbreviations
- GLUT
glucose transporter
- KATP channel
ATP-sensitive potassium channel
- Kir6.x
inwardly rectifying K channel
- SURx
sulfonylurea receptor
References
- 1.Chutkow W A, Simon M C, Le Beau M M, Burant C F. Diabetes. 1996;45:1439–1445. doi: 10.2337/diab.45.10.1439. [DOI] [PubMed] [Google Scholar]
- 2.Seino S. Annu Rev Physiol. 1999;61:337–362. doi: 10.1146/annurev.physiol.61.1.337. [DOI] [PubMed] [Google Scholar]
- 3.Clement J P t, Kunjilwar K, Gonzalez G, Schwanstecher M, Panten U, Aguilar-Bryan L, Bryan J. Neuron. 1997;18:827–838. doi: 10.1016/s0896-6273(00)80321-9. [DOI] [PubMed] [Google Scholar]
- 4.Inagaki N, Gonoi T, Clement J P t, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, Bryan J. Science. 1995;270:1166–1170. doi: 10.1126/science.270.5239.1166. [DOI] [PubMed] [Google Scholar]
- 5.Chutkow W A, Makielski J C, Nelson D J, Burant C F, Fan Z. J Biol Chem. 1999;274:13656–13665. doi: 10.1074/jbc.274.19.13656. [DOI] [PubMed] [Google Scholar]
- 6.Shindo T, Yamada M, Isomoto S, Horio Y, Kurachi Y. Br J Pharmacol. 1998;124:985–991. doi: 10.1038/sj.bjp.0701927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Gross G J. Basic Res Cardiol. 2000;95:280–284. doi: 10.1007/s003950050004. [DOI] [PubMed] [Google Scholar]
- 8.Grover G J. Can J Physiol Pharmacol. 1997;75:309–315. doi: 10.1139/cjpp-75-4-309. [DOI] [PubMed] [Google Scholar]
- 9.Gross G J. Basic Res Cardiol. 1995;90:85–88. doi: 10.1007/BF00789438. [DOI] [PubMed] [Google Scholar]
- 10.Pang C Y, Neligan P, Xu H, He W, Zhong A, Hopper R, Forrest C R. Am J Physiol. 1997;273:H44–H51. doi: 10.1152/ajpheart.1997.273.1.H44. [DOI] [PubMed] [Google Scholar]
- 11.Miki T, Nagashima K, Tashiro F, Kotake K, Yoshitomi H, Tamamoto A, Gonoi T, Iwanaga T, Miyazaki J, Seino S. Proc Natl Acad Sci USA. 1998;95:10402–10406. doi: 10.1073/pnas.95.18.10402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Tybulewicz V L, Crawford C E, Jackson P K, Bronson R T, Mulligan R C. Cell. 1991;65:1153–1163. doi: 10.1016/0092-8674(91)90011-m. [DOI] [PubMed] [Google Scholar]
- 13.Bradley A, Robertson E. Curr Top Dev Biol. 1986;20:357–371. doi: 10.1016/s0070-2153(08)60675-4. [DOI] [PubMed] [Google Scholar]
- 14.Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd Ed. Plainview, NY: Cold Spring Harbor Lab. Press; 1989. [Google Scholar]
- 15.Ohlendieck K, Ervasti J M, Snook J B, Campbell K P. J Cell Biol. 1991;112:135–148. doi: 10.1083/jcb.112.1.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Pi Y, Sreekumar R, Huang X, Walker J W. Circ Res. 1997;81:92–100. doi: 10.1161/01.res.81.1.92. [DOI] [PubMed] [Google Scholar]
- 17.Kim J K, Michael M D, Previs S F, Peroni O D, Mauvais-Jarvis F, Neschen S, Kahn B B, Kahn C R, Shulman G I. J Clin Invest. 2000;105:1791–1797. doi: 10.1172/JCI8305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Hansen P A, Gulve E A, Marshall B A, Gao J, Pessin J E, Holloszy J O, Mueckler M. J Biol Chem. 1995;270:1679–1684. doi: 10.1074/jbc.270.5.1679. [DOI] [PubMed] [Google Scholar]
- 19.Young D A, Uhl J J, Cartee G D, Holloszy J O. J Biol Chem. 1986;261:16049–16053. [PubMed] [Google Scholar]
- 20.Isomoto S, Kondo C, Yamada M, Matsumoto S, Higashiguchi O, Horio Y, Matsuzawa Y, Kurachi Y. J Biol Chem. 1996;271:24321–24324. doi: 10.1074/jbc.271.40.24321. [DOI] [PubMed] [Google Scholar]
- 21.Virkamaki A, Ueki K, Kahn C R. J Clin Invest. 1999;103:931–943. doi: 10.1172/JCI6609. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.St-Denis J F, Cushman S W. J Basic Clin Physiol Pharmacol. 1998;9:153–165. doi: 10.1515/jbcpp.1998.9.2-4.153. [DOI] [PubMed] [Google Scholar]
- 23.Sweeney G, Klip A. Mol Cell Biochem. 1998;182:121–133. [PubMed] [Google Scholar]
- 24.James J H, Fang C H, Schrantz S J, Hasselgren P O, Paul R J, Fischer J E. J Clin Invest. 1996;98:2388–2397. doi: 10.1172/JCI119052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Flatman J A, Clausen T. Nature (London) 1979;281:580–581. doi: 10.1038/281580a0. [DOI] [PubMed] [Google Scholar]
- 26.Moore R D, Rabovsky J L. Am J Physiol. 1979;236:C249–C254. doi: 10.1152/ajpcell.1979.236.5.C249. [DOI] [PubMed] [Google Scholar]
- 27.Otsuka M, Ohtsuki I. Nature (London) 1965;207:300–301. doi: 10.1038/207300a0. [DOI] [PubMed] [Google Scholar]
- 28.Zierler K, Rogus E M. Biochim Biophys Acta. 1981;640:687–692. doi: 10.1016/0005-2736(81)90098-5. [DOI] [PubMed] [Google Scholar]
- 29.Zierler K, Rogus E M, Scherer R W, Wu F S. Am J Physiol. 1985;249:E17–E25. doi: 10.1152/ajpendo.1985.249.1.E17. [DOI] [PubMed] [Google Scholar]
- 30.Zierler K, Rogus E M. Am J Physiol. 1980;239:E21–E29. doi: 10.1152/ajpendo.1980.239.1.E21. [DOI] [PubMed] [Google Scholar]
- 31.Tricarico D, Mallamaci R, Barbieri M, Conte Camerino D. Biochem Biophys Res Commun. 1997;232:536–539. doi: 10.1006/bbrc.1997.6320. [DOI] [PubMed] [Google Scholar]
- 32.Bak J F, Schmitz O, Sorensen N S, Pedersen O. Diabetes. 1989;38:1343–1350. [PubMed] [Google Scholar]
- 33.Salhanick A I, Konowitz P, Amatruda J M. Diabetes. 1983;32:206–212. doi: 10.2337/diab.32.3.206. [DOI] [PubMed] [Google Scholar]
- 34.Kern M, Loomis T A, Tapscott E B, Dohm G L. Int J Biochem. 1993;25:1257–1261. doi: 10.1016/0020-711x(93)90076-q. [DOI] [PubMed] [Google Scholar]
- 35.Wang P H, Moller D, Flier J S, Nayak R C, Smith R J. J Clin Invest. 1989;84:62–67. doi: 10.1172/JCI114170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Vestergaard H, Weinreb J E, Rosen A S, Bjorbaek C, Hansen L, Pedersen O, Kahn B B. J Clin Endocrinol Metab. 1995;80:270–275. doi: 10.1210/jcem.80.1.7829624. [DOI] [PubMed] [Google Scholar]
- 37.Greenfield M S, Doberne L, Rosenthal M, Schulz B, Widstrom A, Reaven G M. Diabetes. 1982;31:307–312. doi: 10.2337/diab.31.4.307. [DOI] [PubMed] [Google Scholar]
- 38.Zierler K, Wu F S. Trans Assoc Am Physicians. 1988;101:320–325. [PubMed] [Google Scholar]
- 39.Tricarico D, Servidei S, Tonali P, Jurkat-Rott K, Camerino D C. J Clin Invest. 1999;103:675–682. doi: 10.1172/JCI4552. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Baron A D, Steinberg H, Brechtel G, Johnson A. Am J Physiol. 1994;266:E248–E253. doi: 10.1152/ajpendo.1994.266.2.E248. [DOI] [PubMed] [Google Scholar]
- 41.Baron A D, Tarshoby M, Hook G, Lazaridis E N, Cronin J, Johnson A, Steinberg H O. Diabetes. 2000;49:768–774. doi: 10.2337/diabetes.49.5.768. [DOI] [PubMed] [Google Scholar]
- 42.Inagaki N, Gonoi T, Clement J P, Wang C Z, Aguilar-Bryan L, Bryan J, Seino S. Neuron. 1996;16:1011–1017. doi: 10.1016/s0896-6273(00)80124-5. [DOI] [PubMed] [Google Scholar]